Fortrea Holdings (FTRE) EBIT (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly EBIT came in at $14.8 million in Q2 2026, up 104.48% YoY from $7.2 million in Q2 2025, and up 535.29% on a QoQ basis from -$3.4 million in Q1 2026.
Fortrea Holdings (FTRE) EBIT (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of EBIT data on file, last reported at $14.8 million in Q2 2026.
- Quarterly EBIT rose 104.48% year-over-year to $14.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$10.8 million (up 98.83% YoY) and the FY2025 annual result came in at -$872.6 million, down 438.97% from the prior year.
- EBIT grew to $14.8 million in Q2 2026, from -$3.4 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $71.2 million in Q2 2022 to a low of -$520.1 million in Q1 2025.
- A 5-year average of -$49.2 million and a median of -$8.6 million in 2025 frame the typical range for EBIT.
- Annual changes were most pronounced in 2025 — EBIT plunged 1290.64% — and 2026, when it soared 104.48%.
- Tracing FTRE's EBIT over 5 years: stood at $14.3 million in 2022, then plunged by 267.83% to -$24.0 million in 2023, then sank by 131.67% to -$55.6 million in 2024, then soared by 75.54% to -$13.6 million in 2025, then surged by 208.82% to $14.8 million in 2026.
- The last three EBIT figures came in at $14.8 million (Q2 2026), -$3.4 million (Q1 2026), and -$13.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 14.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.80 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -13.60 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -330.30 Mn |
| Mar 31, 2025 | -520.10 Mn |
| Dec 31, 2024 | -55.60 Mn |
| Sep 30, 2024 | -18.00 Mn |
| Jun 30, 2024 | -50.90 Mn |
| Mar 31, 2024 | -37.40 Mn |
| Dec 31, 2023 | -24.00 Mn |
| Sep 30, 2023 | 10.30 Mn |
| Jun 30, 2023 | 31.60 Mn |
| Mar 31, 2023 | 14.10 Mn |
| Dec 31, 2022 | 14.30 Mn |
| Sep 30, 2022 | 68.90 Mn |
| Jun 30, 2022 | 71.20 Mn |